Trade Bolt Biotherapeutics, Inc. - BOLT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.0244 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 1.3078 |
| Open* | 1.2978 |
| 1-Year Change* | -55.09% |
| Day's Range* | 1.2978 - 1.3277 |
| 52 wk Range | 1.18-3.14 |
| Average Volume (10 days) | 180.81K |
| Average Volume (3 months) | 5.82M |
| Market Cap | 49.34M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 37.66M |
| Revenue | 4.83M |
| EPS | -2.55 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 24, 2023 | 1.3178 | 0.0200 | 1.54% | 1.2978 | 1.3377 | 1.2978 |
| Mar 23, 2023 | 1.3078 | -0.0598 | -4.37% | 1.3676 | 1.4076 | 1.3078 |
| Mar 22, 2023 | 1.4076 | -0.0599 | -4.08% | 1.4675 | 1.4675 | 1.3776 |
| Mar 21, 2023 | 1.4475 | 0.0499 | 3.57% | 1.3976 | 1.4975 | 1.3776 |
| Mar 20, 2023 | 1.4176 | 0.0200 | 1.43% | 1.3976 | 1.4376 | 1.3676 |
| Mar 17, 2023 | 1.4176 | -0.0499 | -3.40% | 1.4675 | 1.4875 | 1.3976 |
| Mar 16, 2023 | 1.4975 | 0.0699 | 4.90% | 1.4276 | 1.5174 | 1.4176 |
| Mar 15, 2023 | 1.4675 | 0.0699 | 5.00% | 1.3976 | 1.4975 | 1.3976 |
| Mar 14, 2023 | 1.5075 | 0.1099 | 7.86% | 1.3976 | 1.5075 | 1.3976 |
| Mar 13, 2023 | 1.3976 | 0.1098 | 8.53% | 1.2878 | 1.4076 | 1.2678 |
| Mar 10, 2023 | 1.2678 | -0.1198 | -8.63% | 1.3876 | 1.3877 | 1.2678 |
| Mar 9, 2023 | 1.3876 | -0.1298 | -8.55% | 1.5174 | 1.5674 | 1.3677 |
| Mar 8, 2023 | 1.5773 | -0.0200 | -1.25% | 1.5973 | 1.5973 | 1.5274 |
| Mar 7, 2023 | 1.6073 | 0.0599 | 3.87% | 1.5474 | 1.6273 | 1.5474 |
| Mar 6, 2023 | 1.5674 | -0.0898 | -5.42% | 1.6572 | 1.6672 | 1.5174 |
| Mar 3, 2023 | 1.6373 | 0.0200 | 1.24% | 1.6173 | 1.7071 | 1.6173 |
| Mar 2, 2023 | 1.6173 | 0.0400 | 2.54% | 1.5773 | 1.6672 | 1.5773 |
| Mar 1, 2023 | 1.6472 | 0.1298 | 8.55% | 1.5174 | 1.6772 | 1.5174 |
| Feb 28, 2023 | 1.5973 | 0.0799 | 5.27% | 1.5174 | 1.6173 | 1.5174 |
| Feb 27, 2023 | 1.5873 | 0.0499 | 3.25% | 1.5374 | 1.6173 | 1.4874 |
Bolt Biotherapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total revenue | 1.26 | 0.231 | 0.215 | 0 |
| Revenue | 1.26 | 0.231 | 0.215 | 0 |
| Total Operating Expense | 94.048 | 49.413 | 31.184 | 11.629 |
| Selling/General/Admin. Expenses, Total | 18.393 | 9.056 | 5.182 | 2.209 |
| Research & Development | 75.655 | 40.357 | 26.002 | 9.42 |
| Operating Income | -92.788 | -49.182 | -30.969 | -11.629 |
| Interest Income (Expense), Net Non-Operating | 0.281 | 0.199 | 0.524 | 0.193 |
| Other, Net | -6.084 | -11.745 | -0.042 | -0.153 |
| Net Income Before Taxes | -98.591 | -60.728 | -30.487 | -11.589 |
| Net Income After Taxes | -98.591 | -60.728 | -30.487 | -11.589 |
| Net Income Before Extra. Items | -98.591 | -60.728 | -30.487 | -11.589 |
| Net Income | -98.591 | -60.728 | -30.487 | -11.589 |
| Income Available to Common Excl. Extra. Items | -98.591 | -60.728 | -30.487 | -11.589 |
| Income Available to Common Incl. Extra. Items | -98.591 | -60.728 | -30.487 | -11.589 |
| Diluted Net Income | -98.591 | -60.728 | -30.487 | -11.589 |
| Diluted Weighted Average Shares | 33.1967 | 36.3279 | 34.5218 | 34.5218 |
| Diluted EPS Excluding Extraordinary Items | -2.9699 | -1.67166 | -0.88312 | -0.3357 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Diluted Normalized EPS | -2.9699 | -1.67166 | -0.88312 | -0.3357 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0.813 | 0.508 | 0.752 | 0 | 0 |
| Revenue | 0.813 | 0.508 | 0.752 | 0 | 0 |
| Total Operating Expense | 24.689 | 27.583 | 24.278 | 23.761 | 18.426 |
| Selling/General/Admin. Expenses, Total | 6.304 | 5.099 | 4.941 | 4.054 | 4.299 |
| Research & Development | 18.385 | 22.484 | 19.337 | 19.707 | 14.127 |
| Operating Income | -23.876 | -27.075 | -23.526 | -23.761 | -18.426 |
| Interest Income (Expense), Net Non-Operating | 0.198 | -0.082 | 0.131 | 0.176 | 0.056 |
| Other, Net | 0 | 0 | 0 | 0 | -6.084 |
| Net Income Before Taxes | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Net Income After Taxes | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Net Income Before Extra. Items | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Net Income | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Income Available to Common Excl. Extra. Items | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Income Available to Common Incl. Extra. Items | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Diluted Net Income | -23.678 | -27.157 | -23.395 | -23.585 | -24.454 |
| Diluted Weighted Average Shares | 37.1279 | 37.3143 | 37.2068 | 36.5951 | 21.4983 |
| Diluted EPS Excluding Extraordinary Items | -0.63774 | -0.72779 | -0.62878 | -0.64448 | -1.13748 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.63774 | -0.72779 | -0.62878 | -0.64448 | -1.13748 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Total Current Assets | 189.16 | 25.361 | 35.9 | 14.1 |
| Cash and Short Term Investments | 186.219 | 22.838 | 34.826 | 13.634 |
| Cash & Equivalents | 27.383 | 5.542 | 34.826 | 13.634 |
| Short Term Investments | 158.836 | 17.296 | 0 | 0 |
| Prepaid Expenses | 2.941 | 2.523 | 1.074 | 0.466 |
| Total Assets | 307.718 | 46.542 | 48.447 | 15.975 |
| Property/Plant/Equipment, Total - Net | 30.603 | 16.384 | 11.517 | 1.442 |
| Property/Plant/Equipment, Total - Gross | 32.848 | 17.623 | 12.162 | 1.856 |
| Accumulated Depreciation, Total | -2.245 | -1.239 | -0.645 | -0.414 |
| Other Long Term Assets, Total | 2.607 | 4.797 | 1.03 | 0.433 |
| Total Current Liabilities | 21.328 | 11.264 | 8.656 | 2.755 |
| Accounts Payable | 3.574 | 1.598 | 2.095 | 0.892 |
| Accrued Expenses | 14.885 | 8.164 | 5.962 | 1.823 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.04 | ||
| Other Current Liabilities, Total | 2.869 | 1.502 | 0.599 | 0 |
| Total Liabilities | 57.599 | 46.193 | 16.788 | 3.551 |
| Total Long Term Debt | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 36.271 | 34.929 | 8.132 | 0.796 |
| Total Equity | 250.119 | 0.349 | 31.659 | 12.424 |
| Preferred Stock - Non Redeemable, Net | 105.296 | 77.505 | 28.367 | |
| Common Stock | 0.00037 | 0.00036 | 0 | 0 |
| Additional Paid-In Capital | 457.43 | 3.452 | 1.825 | 1.241 |
| Retained Earnings (Accumulated Deficit) | -206.99 | -108.399 | -47.671 | -17.184 |
| Other Equity, Total | -0.32137 | -0.00036 | 0 | 0 |
| Total Liabilities & Shareholders’ Equity | 307.718 | 46.542 | 48.447 | 15.975 |
| Total Common Shares Outstanding | 37.3997 | 36.3279 | 34.5218 | 34.5218 |
| Long Term Investments | 85.348 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 196.088 | 189.16 | 222.488 | 248.151 | 271.21 |
| Cash and Short Term Investments | 190.901 | 186.219 | 212.893 | 244.988 | 266.669 |
| Cash & Equivalents | 44.021 | 27.383 | 23.649 | 58.302 | 95.481 |
| Short Term Investments | 146.88 | 158.836 | 189.244 | 186.686 | 171.188 |
| Prepaid Expenses | 5.187 | 2.941 | 9.595 | 3.163 | 4.541 |
| Total Assets | 282.793 | 307.718 | 333.55 | 347.074 | 324.637 |
| Property/Plant/Equipment, Total - Net | 29.911 | 30.603 | 30.868 | 30.553 | 15.418 |
| Property/Plant/Equipment, Total - Gross | 32.518 | 32.848 | 32.926 | 32.311 | 16.925 |
| Accumulated Depreciation, Total | -2.607 | -2.245 | -2.058 | -1.758 | -1.507 |
| Long Term Investments | 54.313 | 85.348 | 77.639 | 65.938 | 36.236 |
| Other Long Term Assets, Total | 2.481 | 2.607 | 2.555 | 2.432 | 1.773 |
| Total Current Liabilities | 19.306 | 21.328 | 23.695 | 19.25 | 12.012 |
| Accounts Payable | 4.446 | 3.574 | 5.155 | 1.614 | 2.888 |
| Accrued Expenses | 11.412 | 14.885 | 13.333 | 13.306 | 7.622 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 3.448 | 2.869 | 5.207 | 4.33 | 1.502 |
| Total Liabilities | 54.399 | 57.599 | 58.637 | 51.178 | 21.389 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 35.093 | 36.271 | 34.942 | 31.928 | 9.377 |
| Total Equity | 228.394 | 250.119 | 274.913 | 295.896 | 303.248 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Common Stock | 0.00037 | 0.00037 | 0.00037 | 0.00037 | 0.00036 |
| Additional Paid-In Capital | 460.458 | 457.43 | 454.784 | 452.357 | 436.165 |
| Retained Earnings (Accumulated Deficit) | -230.668 | -206.99 | -179.833 | -156.438 | -132.853 |
| Other Equity, Total | -1.39637 | -0.32137 | -0.03837 | -0.02337 | -0.06436 |
| Total Liabilities & Shareholders’ Equity | 282.793 | 307.718 | 333.55 | 347.074 | 324.637 |
| Total Common Shares Outstanding | 37.4713 | 37.3997 | 37.2481 | 37.191 | 36.3318 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Net income/Starting Line | -98.591 | -60.728 | -30.487 | -11.589 |
| Cash From Operating Activities | -57.066 | -47.308 | -26.343 | -9.872 |
| Cash From Operating Activities | 1.193 | 0.611 | 0.335 | 0.302 |
| Non-Cash Items | 19.825 | 15.092 | 1.544 | 0.276 |
| Cash Interest Paid | 0 | 0.004 | ||
| Changes in Working Capital | 20.507 | -2.283 | 2.265 | 1.139 |
| Cash From Investing Activities | -232.201 | -20.592 | -0.508 | -0.29 |
| Capital Expenditures | -2.338 | -3.262 | -0.508 | -0.29 |
| Other Investing Cash Flow Items, Total | -229.863 | -17.33 | 0 | 0 |
| Cash From Financing Activities | 311.108 | 39.597 | 48.627 | 19.094 |
| Financing Cash Flow Items | 0 | 39.303 | 48.595 | 19.113 |
| Issuance (Retirement) of Stock, Net | 311.108 | 0.294 | 0.072 | 0.02 |
| Issuance (Retirement) of Debt, Net | 0 | -0.04 | -0.039 | |
| Net Change in Cash | 21.841 | -28.303 | 21.776 | 8.932 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -23.678 | -98.591 | -71.434 | -48.039 | -24.454 |
| Cash From Operating Activities | -24.314 | -57.066 | -39.272 | -20.545 | -16.559 |
| Cash From Operating Activities | 0.357 | 1.193 | 0.832 | 0.528 | 0.272 |
| Non-Cash Items | 4.556 | 19.825 | 16.21 | 12.401 | 8.994 |
| Changes in Working Capital | -5.549 | 20.507 | 15.12 | 14.565 | -1.371 |
| Cash From Investing Activities | 40.845 | -232.201 | -253.234 | -237.123 | -190.521 |
| Capital Expenditures | -0.605 | -2.338 | -1.776 | -0.761 | -0.058 |
| Other Investing Cash Flow Items, Total | 41.45 | -229.863 | -251.458 | -236.362 | -190.463 |
| Cash From Financing Activities | 0.107 | 311.108 | 310.613 | 310.428 | 297.019 |
| Issuance (Retirement) of Stock, Net | 0.107 | 311.108 | 310.613 | 310.428 | 297.019 |
| Net Change in Cash | 16.638 | 21.841 | 18.107 | 52.76 | 89.939 |
| Financing Cash Flow Items | 0 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Vivo Capital, LLC | Venture Capital | 10.2793 | 3871291 | 0 | 2022-12-31 | MED |
| Sofinnova Investments, Inc | Venture Capital | 7.3138 | 2754437 | 0 | 2022-12-31 | MED |
| Citadel Advisors LLC | Hedge Fund | 7.3077 | 2752162 | 114 | 2022-12-31 | HIGH |
| Pivotal Bioventure Partners Investment Advisor LLC | Investment Advisor | 5.0224 | 1891467 | 0 | 2022-12-31 | LOW |
| Engleman Edgar G | Individual Investor | 3.2402 | 1220280 | -57947 | 2022-03-01 | |
| Nan Fung Group Holdings Ltd | Corporation | 3.0986 | 1166952 | 0 | 2022-12-31 | LOW |
| Newtyn Management, LLC | Hedge Fund | 3.0536 | 1150000 | 550000 | 2022-12-31 | MED |
| Samsara BioCapital, LLC | Venture Capital | 2.7858 | 1049153 | 0 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.4648 | 928276 | -11993 | 2022-12-31 | LOW |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 2.0474 | 771059 | 0 | 2022-12-31 | LOW |
| Stanford Management Company | Endowment Fund | 1.9106 | 719546 | 0 | 2022-12-31 | MED |
| Renaissance Technologies LLC | Hedge Fund | 1.1724 | 441539 | 47681 | 2022-12-31 | HIGH |
| Hawkeye Capital Management, LLC | Hedge Fund | 1.102 | 415039 | 0 | 2022-12-31 | MED |
| Tang Capital Management, LLC | Hedge Fund | 1.0621 | 400000 | 200000 | 2022-12-31 | MED |
| Goldman Sachs & Company, Inc. | Research Firm | 0.7515 | 283028 | 270883 | 2022-12-31 | MED |
| Oasis Management Company Ltd. | Investment Advisor/Hedge Fund | 0.7435 | 280000 | 0 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.7131 | 268547 | -153412 | 2022-12-31 | LOW |
| Millennium Management LLC | Hedge Fund | 0.6463 | 243401 | 125022 | 2022-12-31 | HIGH |
| Assenagon Asset Management S.A. | Investment Advisor | 0.5996 | 225816 | -54165 | 2022-12-31 | HIGH |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.4981 | 187600 | 74400 | 2022-12-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group500K+
Traders
92K+
Active clients monthly
$53M+
Monthly investing volume
$30M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Bolt Biotherapeutics, Inc. Company profile
About Bolt Biotherapeutics Inc
Bolt Biotherapeutics, Inc is a clinical-stage immuno-oncology company. The Company is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Its Immune-Stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. The Company’s product candidate BDC-1001 is a human epidermal growth factor receptor 2 (HER2) Boltbody ISAC comprised of a HER2-targeting biosimilar, of trastuzumab conjugated to one of its TLR7/8 agonists, for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. Its Toll-like receptors (TLRs) activate myeloid cells and enable the presentation of tumor-associated neoantigens to cytotoxic T cells.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Bolt Biotherapeutics Inc revenues increased from $231K to $752K. Net loss increased from $29.7M to $71.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and d increase of 99% to $49.8M (expense), Fair Value Adjustments on Other Assets decrease from $2.4M (income) to $6.1M (expense).
| Industry: | Bio Therapeutic Drugs |
900 Chesapeake Drive
REDWOOD CITY
CALIFORNIA 94063
US
Income Statement
- Annual
- Quarterly
News
GBP/EUR forecast: Will the pound rise against the euro in 2023?
The British pound has been moving sideways against the Euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
16:27, 24 March 2023
Shiba Inu price prediction: Can the meme coin build on recent gains?
What’s next for the Shiba Inu meme coin after a sluggish 2022 so far? Read more…
12:51, 24 March 2023
Who are the biggest bitcoin mining companies?
Bitcoin mining is big business, but who are the biggest bitcoin mining companies?
12:06, 24 March 2023
USD/PKR forecast: Will Pakistan’s rupee continue to fall?
The rupee has rebounded against the dollar in recent months, will this trend continue?
11:49, 24 March 2023
Amazon stock forecast: Where next for AMZN amid massive layoffs?
Amazon has been making tens of thousands of its workers redundant. Does this affect the market’s baseline Amazon stock forecast?
10:46, 24 March 2023
Sweatcoin price prediction: What is Sweatcoin?
Can Sweatcoin run to the front of the crypto pack?
15:19, 23 March 2023
Who owns the most bitcoin?
Want to know who owns the most bitcoin? Learn more about the biggest bitcoin whales.
14:54, 23 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com